Trial · NCT02536976

Mirabegron in Parkinson Disease and Impaired Cognition

NCT02536976, Phase 4, Completed, HealthPartners Institute; results first posted 2019-05-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Mirabegron in Parkinson Disease and Impaired Cognition. Trials, record NCT02536976. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02536976

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Mirabegron in Parkinson Disease and Impaired Cognition
NCT number: NCT02536976
Status: Completed
Phases: Phase 4
Enrollment: 7 participants, actual
Lead sponsor: HealthPartners Institute
Conditions: Parkinson Disease, Overactive Bladder, Impaired Cognition
Interventions: mirabegron, Placebo
First posted: 2015-09-01
Last updated: 2019-05-08
Results first posted: 2019-05-08
Limitations and caveats: Study closed before reaching target enrollment. Due to the small number of participants enrolled no statistical analysis was performed, therefore no conclusions can be obtained.

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Montreal Cognitive Assessment Total Score	From Week 2 to Week 14	Change in Montreal Cognitive Assessment Total Score between week 2 and week 14. The Montreal Cognitive Assessment is a screening tool for global cognitive function with a total score ranging from 0 to 30 units on a scale, with higher score indicating better cognitive global function. Normal range is 26 thru 30.
Secondary	Change in Overactive Bladder Questionnaire Subscale Scores	From Week 2 to Week 14	The Overactive Bladder Questionnaire (OABQ) is a 33-item, self-administered instrument that contains a symptom bother scale (8 items) and a health-related quality of life (HRQL) scale (25 items), pertaining to OAB symptoms impact on HRQL. Symptom bother score ranges from 0-100 with higher scores indicating greater severity of symptoms. The HRQL score ranges from 0-100 with higher scores indicating better quality of life.
Secondary	Change in Unified Parkinson's Disease Rating Scale	From Week 2 to Week 14	The UPDRS assesses motor and functional abilities of the subjects as it pertains to Parkinson's disease. The total UPDRS score (range 0-199; defined for this study as the sum of Parts I, II, III, and IV (I-Mentation, behavior, and mood section (4 items; range 0-16); II-Activities of Daily Living (ADL; 13 items; range 0-52); III-motor section (27 items; range 0-108) and IV-complications section; 11 items; range 0-23) will be completed by history and examination. Higher scores indicate greater severity of Parkinson's disease symptoms.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Montreal Cognitive Assessment Total Score	From Week 2 to Week 14	units on a scale	MEAN
SECONDARY	Change in Overactive Bladder Questionnaire Subscale Scores	From Week 2 to Week 14	units on a scale	MEAN
SECONDARY	Change in Unified Parkinson's Disease Rating Scale	From Week 2 to Week 14	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Montreal Cognitive Assessment Total Score	Active Treatment		1.5	Full Range -1 to 2	units on a scale
Change in Montreal Cognitive Assessment Total Score	Placebo		2	Full Range 2 to 2	units on a scale
Change in Overactive Bladder Questionnaire Subscale Scores	Active	Symptom Severity	-13.3	Full Range -25 to 5	units on a scale
Change in Overactive Bladder Questionnaire Subscale Scores	Placebo	Symptom Severity	12.5	Full Range 12.5 to 12.5	units on a scale
Change in Overactive Bladder Questionnaire Subscale Scores	Active	HRQL	13.7	Full Range 0 to 25	units on a scale
Change in Overactive Bladder Questionnaire Subscale Scores	Placebo	HRQL	5	Full Range 5 to 5	units on a scale
Change in Unified Parkinson's Disease Rating Scale	Active		-5.3	Full Range -16 to 6	units on a scale
Change in Unified Parkinson's Disease Rating Scale	Placebo		-9	Full Range -9 to -9	units on a scale

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Active Treatment	3
Overall Study	STARTED	Placebo	2
Overall Study	Randomization	Active Treatment	3
Overall Study	Randomization	Placebo	1
Overall Study	Dose Escalation and Maintenance	Active Treatment	3
Overall Study	Dose Escalation and Maintenance	Placebo	1
Overall Study	Washout	Active Treatment	3
Overall Study	Washout	Placebo	1
Overall Study	COMPLETED	Active Treatment	3
Overall Study	COMPLETED	Placebo	1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Pneumonia	Respiratory, thoracic and mediastinal disorders	Active Treatment	0	3	0
other	Pneumonia	Respiratory, thoracic and mediastinal disorders	Placebo	1	2	1
other	hyponatremia	Metabolism and nutrition disorders	Active Treatment	0	3	0
other	hyponatremia	Metabolism and nutrition disorders	Placebo	1	2	1
other	Diarrhea	Gastrointestinal disorders	Active Treatment	0	3	0
other	Diarrhea	Gastrointestinal disorders	Placebo	1	2	1
other	constipation	Gastrointestinal disorders	Active Treatment	0	3	0
other	constipation	Gastrointestinal disorders	Placebo	1	2	1
other	headache	Nervous system disorders	Active Treatment	0	3	0
other	headache	Nervous system disorders	Placebo	1	2	1

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Active Treatment	0	3
Total, all-cause mortality	Placebo	0	2
Total, other adverse events	Active Treatment	0	3
Total, other adverse events	Placebo	2	2
Total, serious adverse events	Active Treatment	0	3
Total, serious adverse events	Placebo	0	2

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Active Treatment vs Placebo: deaths from any cause	Trial comparisons
Active Treatment vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02536976

GET https://conductscience.org/api/trials/v1/NCT02536976/registered

API reference For AI assistants